Abstract
The mitogen-activated protein kinase signalling pathway is a central regulator of tumor growth, which is constitutively activated in chemically induced mouse liver tumors. In about 30–50% of cases this effect can be related to activation of the Ha-ras gene by point mutations, whereas in the remaining cases mutations may occur in other members within this pathway, such as Raf kinases. Recently, B-raf has been shown to be frequently mutated in human melanomas and certain other cancers, with a V599E amino-acid change representing the most predominant mutation type. We now screened 82 N-nitrosodiethylamine-induced liver tumors from C3H/He mice for mutations within the hotspot positions in the Ha-ras and B-raf genes. About 50% (39/82) of tumors showed Ha-ras codon 61 mutations and 16 tumors (∼20%) harbored mutations at codon 624 of the B-raf gene, which corresponds to codon 599 in human B-raf. None of the tumors was mutated in both Ha-ras and B-raf. The high prevalence of Ha-ras and B-raf mutations in mouse liver tumors is in striking contrast to human hepatocellular cancers which very infrequently harbor mutations in the two genes. These fundamental differences between the biology of liver tumors in mice and man may be of toxicological relevance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bauer-Hofmann R, Klimek F, Buchmann A, Müller O, Bannasch P and Schwarz M . (1992). Mol. Carcinogen., 6, 60–67.
Berg LM, Sanders R and Alderborn A . (2002). Expert Rev. Mol. Diagn., 2, 361–369.
Buchmann A, Bauer-Hofmann R, Mahr J, Drinkwater NR, Luz A and Schwarz M . (1991). Proc. Natl. Acad. Sci. USA, 88, 911–915.
Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R and McCubrey JA . (2003). Int. J. Oncol., 22, 469–480.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard Jones K, Maitland N, Chenevix Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA . (2002). Nature, 417, 949–954.
Downward J . (1998). Curr. Opin. Genet. Dev., 8, 49–54.
Downward J . (2003). Nat. Rev. Cancer, 3, 11–22.
Dragani TA, Manenti G, Colombo BM, Falvella FS, Gariboldi M, Pierotti MA and Della Porta G . (1991). Oncogene, 6, 333–338.
Erhardt P, Schremser EJ and Cooper GM . (1999). Mol. Cell. Biol., 19, 5308–5315.
Frey S, Buchmann A, Bursch W, Schulte-Hermann R and Schwarz M . (2000). Carcinogenesis, 21, 161–166.
Hagemann C and Rapp UR . (1999). Exp. Cell Res., 253, 34–46.
Hunter T . (1997). Cell, 88, 333–346.
Hüser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S, Sun XM, Brown J, Marais R and Pritchard C . (2001). EMBO J., 20, 1940–1951.
Kalkuhl A, Troppmair J, Buchmann A, Stinchcombe S, Buenemann CL, Rapp UR, Kaestner K and Schwarz M . (1998). Hepatology, 27, 1081–1088.
Malumbres M and Barbacid M . (2003). Nat. Rev. Cancer, 3, 459–465.
Maronpot RR, Fox T, Malarkey DE and Goldsworthy TL . (1995). Toxicology, 101, 125–156.
Mercer KE and Pritchard CA . (2003). Biochim. Biophys. Acta, 1653, 25–40.
Mikula M, Schreiber M, Husak Z, Kucerova L, Rüth J, Wieser R, Zatloukal K, Beug H, Wagner EF and Baccarini M . (2001). EMBO J., 20, 1952–1962.
O'Neill E and Kolch W . (2004). Br. J. Cancer, 90, 283–288.
Schwarz M, Buchmann A, Stinchcombe S, Luebeck G, Moolgavkar S and Bock KW . (1995). Mutat. Res., 333, 69–79.
Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J and Wittekind C . (2003). Gut, 52, 706–712.
Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D and Marais R . (2004). Cell, 116, 855–867.
Wang H-G, Miyashita T, Takayama S, Sato T, Torigoe T, Krajewski S, Tanaka S, Hovey III L, Troppmair J, Rapp UR and Reed JC . (1994). Oncogene, 9, 2751–2756.
Wang HG, Rapp UR and Reed JC . (1996). Cell, 87, 629–638.
Xiao W and Oefner PJ . (2001). Hum. Mutat., 17, 439–474.
Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R and Leung SY . (2002). Cancer Res., 62, 6451–6455.
Acknowledgements
The excellent technical assistance of Mrs E Zabinsky and Mr M Niwar is acknowledged. We also thank Thomas Franck for his support in dHPLC analysis. This study was supported by the Deutsche Forschungsgemeinschaft (SCHW 329/3-1) to MS.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jaworski, M., Buchmann, A., Bauer, P. et al. B-Raf and Ha-ras mutations in chemically induced mouse liver tumors. Oncogene 24, 1290–1295 (2005). https://doi.org/10.1038/sj.onc.1208265
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208265
Keywords
This article is cited by
-
Current view of liver cancer cell-of-origin and proposed mechanisms precluding its proper determination
Cancer Cell International (2023)
-
The DNA methylation profile of liver tumors in C3H mice and identification of differentially methylated regions involved in the regulation of tumorigenic genes
BMC Cancer (2018)
-
Dietary restriction protects against diethylnitrosamine-induced hepatocellular tumorigenesis by restoring the disturbed gene expression profile
Scientific Reports (2017)
-
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME
Archives of Toxicology (2013)
-
The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development
The EMBO Journal (2007)